The field of nonprecious metal catalysis (NPMC) continues to provide alternatives to transformations that are traditionally mediated by precious metals, as well as reactivity unique to the first-row transition metals. These advances are of interest due to their lower cost, better sustainability, and expanding range of applications. This review is part of a triannual series published by chemists from AbbVie, Boehringer-Ingelheim, and Pfizer focused on NPMC articles selected for their utility to the chemical and pharmaceutical industries from November 2024 to February 2025.
Allais et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: